

ALPIC 2025

Advanced Learning on Platelets & Thrombosis International Course

28th - 30th November 2025

Divani Meteora Hotel

**KALAMPAKA
GREECE**

Organizer:



European and Mediterranean League
Against Thrombotic Diseases

Course Directors:

Georgia Kaiafa

Associate Professor
of Haematology &
Thromboembolic Diseases
AHEPA University Hospital
Aristotle University
of Thessaloniki

Christos Savopoulos

Professor of Internal Medicine
Director of 1st Medical
Propedeutic Dept of Internal
Medicine, Excellence Center
of Hypertension & Stroke Unit
Aristotle University of Thessaloniki
AHEPA University Hospital

Alexandros Tselepis

Professor Emeritus
of the University
of Ioannina, Member
of EMLTD Society,
Executive Committee

Under the Auspices of:



Hellenic
Cardiological Society



Hellenic Society
of Haematology



Internal Medicine
Society of Greece

The Congress will be accredited
with **19.5 (ECME Credits)**
by the Panhellenic Medical Association

Scientific Program

ALPIC ORGANIZER



European and Mediterranean League
Against Thrombotic Diseases

■ Course Directors:

Georgia Kaiafa

Associate Professor
of Haematology &
Thromboembolic Diseases
AHEPA University Hospital
Aristotle University
of Thessaloniki

Christos Savopoulos

Professor of Internal
Medicine Director
of 1st Medical Propedeutic
Dept of Internal Medicine,
Excellence Center
of Hypertension & Stroke
Unit Aristotle University
of Thessaloniki AHEPA
University Hospital

Alexandros Tselepis

Professor Emeritus
of the University
of Ioannina, Member
of EMLTD Society,
Executive Committee

■ Local Organizing Committee:

Despoina Adamidou

Eleni Arnaoutoglou

Vasiliki Danilatos

Nikolaos Fragakis

Fotis Girtovitis

Elisavet Grouzi

Styliani Kokori

Elias Kyriakou

Eleftheria Lefkou

Evdokia Mandala

Miltiadis Matsagkas

Efrosyni Nomikou

Matina Pagoni

Emmanouil Papadakis

Dimitrios Papazoglou

Vasileios Perifanis

Konstantinos Toutouzas

Stavroula Tsiara

Sofia Vakalopoulou

George Vassilopoulos

Efthymia Vlachaki

Ioannis Zarifis

Antonios Ziakas

Here's why! See you in Kalampaka for what promises to be a most exciting congress!

The scientific program is focused on realistic views of controversial issues in thrombosis and antithrombotic therapy. The ALPIC 2025 scientific programme includes a combination of Keynote lectures, Plenary Sessions, Interactive Workshops, Clinical Seminars and How to Treat Sessions, as well as Meet the Experts Sessions presented by a faculty of internationally renowned leaders.

Dear Colleagues,

We are pleased to welcome you to **ALPIC 2025 (Advanced Learning on Platelets & Thrombosis International Course)**, the 15th international scientific event on Platelets and Thrombosis, taking place this year in **Kalampaka, Greece**, at the **Divani Meteora Hotel**, on **November 28 - 30, 2025**. ALPIC 2025 is organized by the European and Mediterranean League against Thrombotic Diseases (EMLTD), having as Course Directors Professors Georgia Kaiafa, Christos Savopoulos and Alexandros Tselepis. ALPIC 2025 aims to serve as a knowledge transfer forum for scientists in the current aspects of Platelet and Thrombosis research, ranging from basic and translational science to the clinical practice. The scientific program is designed to highlight the rapid development and ongoing evolution on the pathophysiological and clinical aspects of Thrombosis and Haemostasis along with discussion regarding all current advances in Antiplatelet and Anticoagulant therapy. We are very pleased and proud that ALPIC has gained worldwide warm acceptance and recognition for its scientific merit, and we do hope that ALPIC 2025 will further strengthen the European and Mediterranean network for Thrombosis and Antithrombotic Therapy in basic and translational research as well as in clinical practice. ALPIC 2025 is organized under the auspices of the Hellenic Cardiological Society, the Hellenic Society of Haematology and the Internal Medicine Society of Greece. The congress will give us the opportunity to bring together scientists and experts having a wide spectrum of disciplines, who will share current knowledge on various aspects of Thrombosis. The ALPIC 2025 Directors as well as the Members of the Local Organizing Committee, consisting of experts in thrombosis with different specialties, have created an attractive and comprehensive scientific program with care and appreciation for attendees' scientific and personal enjoyment. An internationally recognized panel of invited speakers will present state-of-the-art lectures and will create an excellent opportunity for all participants to stimulate an extended and very constructive discussion both inside and outside the lecture hall. The Organizers will spare no efforts to ensure that ALPIC 2025 will be an exciting and enriching experience for all participants. It's our great pleasure to welcome you to Kalampaka and we wish you to enjoy ALPIC 2025.

With our best regards,

The ALPIC 2025 Directors

Georgia Kaiafa

Associate Professor
of Haematology &
Thromboembolic Diseases
AHEPA University Hospital
Aristotle University
of Thessaloniki

Christos Savopoulos

Professor of Internal Medicine
Director of 1st Medical
Propedeutic Dept of Internal
Medicine, Excellence Center
of Hypertension & Stroke Unit
Aristotle University of Thessaloniki
AHEPA University Hospital

Alexandros Tselepis

Professor Emeritus
of the University
of Ioannina,
Member of EMLTD Society,
Executive Committee

Friday, November 28th, 2025

10.30 **Registrations**

11.00-13.15 **The Most Impactful Studies in Thrombosis and Antithrombotic Therapy in 2024-2025**

Chairs: Christos **Savopoulos**, Georgia **Kaiafa**, Alexandros **Tselepis**, Ioannis **Styliadis**

STOPDAPT-3. An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting
Stylianos **Daios**

PRESTIGE-AF. DOACs versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with AF: A multicentre, open-label, randomised, phase 3 trial
Aikaterini **Triantafyllou**

REC-CAGEFREE II. Stepwise DAPT de-escalation in patients after drug coated balloon angioplasty: A multicentre, randomised, open label, assessor blind, non-inferiority trial
Spyridon-Filippos **Papadopoulos**

POPular PAUSE TAVI. Continuation versus Interruption of Oral Anticoagulation during TAVI. The study favours peri-TAVI OAC discontinuation
Matthaios **Didagelos**

PEERLESS. A Randomized Controlled Trial comparing Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism
Thomas **Zegkos**

ACE-PROTAVI. Randomized Clinical Trial for Routine Protamine Administration for Bleeding in Transcatheter Aortic Valve Implantation
Antonios **Kouparanis**

START. Strategies for anticoagulation in patients with thrombocytopenia and cancer-associated thrombosis: design and rationale of the START pilot randomized controlled trial
Stavroula **Bountola**

Friday, November 28th, 2025

CREATE. This trial is investigating the discontinuation of antithrombotic therapy after transcatheter aortic valve replacement (TAVR) in patients without a long-term need for anticoagulation or antiplatelet therapy
Charalampos **Kakderis**

DEFIANCE. A randomized controlled trial of mechanical thrombectomy versus anticoagulation alone for iliofemoral deep vein thrombosis. Rationale and design of the study
Argyrios **Giannopoulos** 

STOP-CAD. Antithrombotic therapy for stroke prevention in cervical artery dissection. This trial explores antithrombotic strategies for stroke prevention in patients with cervical artery dissection
Iason **Gravanis- Apostolopoulos**

FRAIL-AF. A Randomized Controlled Trial which evaluated the Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation
Anastasia **Kontana**

OPTIMAS. A multicentre, blinded-endpoint, phase 4, randomised controlled trial which investigated the efficacy and safety of early compared with delayed initiation of DOACs in patients with acute ischaemic stroke associated with atrial fibrillation
Korina **Kaffe**

PROTECT-HBR. Rationale and design of a randomized trial comparing the efficacy and safety of a potassium-competitive acid blocker versus a proton-pump inhibitor in patients receiving antithrombotic therapy who are at high risk for gastrointestinal bleeding
Vaia **Kyritsi**

ATTEST-2. A randomised, parallel group, open-label trial which compared tenecteplase versus alteplase for acute stroke within 4-5 h of onset
Dimitra **Papadimitriou**

Friday, November 28th, 2025

13.15-14.30 Research in Progress

Chairs: Stefanos-Konstantinos **Mylonas**, Georgia **Kaiafa**,
Dimitrios **Papazoglou**

North Kynouria Project
Anna-Maria **Louka**

The effect of puniic acid from pomegranate seed oil on oxidative stress and endothelial dysfunction in type II diabetes
Vasileios **Patriarcheas**

ADAMTs 13 activity and endothelial markers in acute ischemic stroke
Evangelos-Michail **Makris**

Key studies shaping the treatment of aggressive Lymphomas
Vasiliki **Gougoula**

IPF in acute ischemic stroke
Alexandra **Tsankof**

Differential effect of EPA, DHA and their combination with DOACs on platelet inhibition, in vitro
Ioannis **Koutsaliaris**

14.30-15.00 Break-Light Lunch

15.00-16.00 Clots and Bugs: Where infection meets Coagulation

Chair: Stavroula **Tsiara**

Platelets and antiplatelets in sepsis: a glimpse into the future
Karolina **Akinosoglou**

Immunothrombosis and endotheliopathy in infectious diseases: exploring the last frontier
Dimitrios **Pilalas**

Commentator: Michalis **Anthopoulos**

ALPIC 2025

SCIENTIFIC PROGRAMME

Friday, November 28th, 2025

16.00-16.30 Lecture

Chair: Dimitrios **Tsakiris** 

New targets for antithrombotic medications: Seeking to decouple thrombosis from hemostasis

Alexandros **Tselepis**

16.30-18.00 Thrombotic risk in hematologic and immune diseases. In Collaboration with Hellenic Society of Haematology

Chairs: George **Vassilopoulos**, Evdoxia **Hatjiharissi** 

Pathophysiology of thrombosis in myeloproliferative neoplasms

Nikolaos **Sousos** 

Thrombotic anti-PF4 immune disorders

Dorothee **Faille** 

Monoclonal Gammopathy of Thrombotic and Bleeding Significance

Vasiliki **Gkalea**

Commentator: Charalampos **Pontikoglou** 

18.00-18.30 Coffee Break

18.30-20.00 Keynote Lectures

Chairs: Alexandros **Tselepis**, Elisavet **Grouzi**

Anticoagulants: successes, failures and future promises

James **Douketis** 

Stents and Surgery: The dimension of the problem from different clinical points of view

Eleni **Arnaoutoglou**

Cancer associated thrombosis: what anticoagulant to choose?

Miltiadis **Matsagkas**

 : Virtual Participation

Friday, November 28th, 2025

20.00-20.30 Official Opening of ALPIC 2025

Chairs: Georgia **Kaiafa**, Christos **Savopoulos**, Alexandros **Tselepis**

President of the EMLTD Society

Joao **Morais**

Chair of ETHA

Mettine **Bos** 

President of the Hellenic Cardiological Society

Konstantinos **Toutouzas** 

President of the Hellenic Society of Haematology

George **Vassilopoulos**

President of the Internal Medicine Society of Greece

Matina **Pagoni** 

Mayor of the Municipality of Meteora

Eleftherios N. **Avramopoulos**

20.30-21.00 Opening Lecture

Chairs: Christos **Savopoulos**, Alexandros **Tselepis**

Antithrombotic drugs for ACS in women

Joao **Morais**

21.00 **Dinner**

Saturday, November 29th, 2025

09.00-10.00 Complement activation as a trigger of immunothrombosis in specific entities -new insights in diagnosis and treatment.

Chairs: Elisavet **Grouzi**, Vasiliki **Danilatou**

Antiphospholipid syndrome

Eleftheria **Lefkou**

Paroxysmal nocturnal hemoglobinuria

Styliani **Kokori**

Atypical HUS

Eleni **Gavriilaki** 

10.00-11.00 Lifestyle and thrombosis

Chairs: Efrosyni **Nomikou**, Emmanouil **Papadakis**

Dietary habits and thrombosis

Vaia **Lambadiari** 

VTE management in obesity

Efrosyni **Nomikou**

Addictions and thrombosis

Vasiliki **Danilatou**

11.00-11.30 Coffee Break

11.30-12.30 Management of thrombosis and bleeding in challenging patient populations

Chairs: Fotios **Girtovitis**, Elias **Kyriakou**

Management of VTE in ICU patients

Maria **Melissopoulou**

Management of anticoagulation in "end of life" patients

Emmanouil **Papadakis**

Bleeding emergencies in Haematological patients

Georgia **Kaiafa**

Commentator: Maria **Topalidou**

Saturday, November 29th, 2025

12.30-13.00 Lecture

Chair: Georgia **Kaiafa**

Platelet -omics in health and disease

Elias **Kyriakou**

13.00-14.40 Clinical Seminar: Uncertainties and challenges in anticoagulation therapy

Chairs: Sofia **Vakalopoulou** , Evdokia **Mandala**

Direct oral anticoagulants in patients with severe inherited thrombophilia

Despoina **Adamidou**

Anticoagulation in patients with cirrhosis

Adonis **Protopapas**

The risk of thrombosis and the choice of antithrombotic therapy in patients with multiple myeloma

Eirini **Katodritou**

Thromboinflammation in sickle cell disease and its complications

Efthymia **Vlachaki**

When and how to reverse anticoagulants

Vasileios **Perifanis**

14.40-16.15 Break-Light Lunch

Saturday, November 29th, 2025

16.15-17.45 Interactive EMLTD Workshop. Thrombosis – special aspects in special populations (online session)

Speakers are Country Councilors from countries affiliated with EMLTD

Chairs: Gili **Kenet** , Georgia **Kaiafa**

Unique aspects in thrombosis diagnosis and treatment among children and adolescents

Christof **Male** 

The use of direct oral anticoagulants in patients with unusual site thrombosis

Omri **Cohen** 

Cerebral sinus vein thrombosis – differences between pediatric and adult patients

Sarina **Levy-Mendelovich** 

17.45-18.15 Keynote Lecture

Chairs: Christos **Savopoulos**, Alexandros **Tselepis**

Reversal of antiplatelet therapy for major bleeds or emergent procedures

Alex **Spyropoulos** 

18.15-18.45 Coffee Break

Saturday, November 29th, 2025

18.45-20.15 **Meet the Experts. Metabolic disorders and Atherothrombosis. Pathophysiology, Clinical consequences and Current treatment options**

Chairs: Dimitrios **Skoutas** , Ioannis **Kyriazis** 

Obesity, platelet functionality and thrombosis risk. Management options

Charikleia **Dimitroula** 

The complex interaction between hypertension, dyslipidemia, platelet functionality and coagulation cascade. Clinical consequences

Areti **Triantafyllou**

Effect of major hypolipidemic drugs on thrombosis parameters

Implication for cardiovascular risk reduction

Dimitrios **Agapakis** 

Atherothrombosis risk in smokers – New data

Ignatios **Ikonomidis** 

The Anti-Thrombotic Effects of PCSK9 Inhibitors

Matilda **Florentin**

20.15-20.45 **Satellite Lecture**

(page 15)

21.00 **Dinner**

Sunday, November 30th, 2025

09.15-10.30 **Plenary session: Adjunctive antiplatelet therapy for patients undergoing PCI**

Chairs: Lampros **Michalis** , Antonios **Ziakas**,
Konstantinos **Toutouzas** 

Management of asymptomatic atrial fibrillation
Nikolaos **Fragakis**

Impact of antiplatelet pretreatment on stent thrombosis in patients undergoing PCI in real world practice
Kallirroi **Kalantzi** 

Aspirin reloading before PCI on chronic aspirin therapy reduces early ischemia without bleeding trade-off
Dimitrios **Nikas**

1-Month vs. 12-month DAPT: comparative outcomes after aspirin cessation with supreme healing-targeted stent
Ioannis **Zarifis** 

Commentator: Konstantinos **Pappas**

10.30-11.00 **Lecture**

Chair: Dimitrios **Zafeiriou** 

Thromboprophylaxis in children with cancer: What's new
Emmanouel **Hatzipantelis**

Sunday, November 30th, 2025

11.00-12.30 Clinical Seminar: Diabetes Mellitus

Chairs: Triantafyllos **Didangelos**, Matina **Pagoni** 

Diabetic Neuropath

Triantafyllos **Didangelos**

Diabetic Nephropathy

Eleni **Karlafti**

Diabetes Mellitus and Stroke

Thomas **Tegos** 

Diabetes Mellitus, Arterial Hypertension and Macroangiopathy

Zisis **Kontoninas**

Antithrombotic therapy in diabetes

Eleftheria **Ztriva**

Commentators: Zadal **Mouslech**, Adamantios **Bourdakis**

12.30-14.15 How to Treat Session. Practical Guidance in Stroke Patients

Chairs: Thomas **Tegos** , Xenofon **Krokidis**

Thrombolysis in acute ischemic stroke

Nikolaos **Kakaletsis**

Blood pressure management in acute stroke

Maria **Kosmidou** 

Antiplatelets in ischemic stroke

Dimitrios **Sagris**

Anticoagulants in ischemic stroke

Eleni **Korompoki** 

Commentator: Georgios **Polychronopoulos**

14.15-15.30 **End of ALPIC 2025**

Saturday, November 29th, 2025

20.15-20.45 **Satellite Lecture**



Chair: Anastasia **Banti**

BTKis and cardiovascular events in CLL: The role of BTKis selectivity and treatment duration

Christos **Lafaras**

Tagrol®

τικαγρελόρη



Ισχυρό
στήριγμα
ζωής*

ΠΡΟΪΟΝ	Λ.Τ.
TAGROL® F.C.TAB 60MG/TAB BT X 56 TABS	41,57 €
TAGROL® F.C.TAB 90MG/TAB BT X 60 TABS	47,36 €



ΕΛΠΕΝ Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ
Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής
Τηλ.: 210 6039326-9, Fax: 210 6039300
www.elpen.gr

ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ
Σεβαστείας 11, 115 28 Αθήνα
Τηλ.: 210 7488711, Fax: 210 7488731
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη
Τηλ. 2310 459920-1, Fax: 2310 459269

**ΦΑΡΜΑΚΕΥΤΙΚΑ ΠΡΟΪΟΝΤΑ
ΓΙΑ ΤΑ ΟΠΟΙΑ ΑΠΑΙΤΕΙΤΑΙ ΙΑΤΡΙΚΗ ΣΥΝΤΑΓΗ**

* Για τις συνταγογραφικές πληροφορίες συμβουλευτείτε την Περίληψη
Χαρακτηριστικών του Προϊόντος σκανάροντας τον **QR κωδικό**

Αναφέρετε κάθε εικαζόμενη/πιθανολογούμενη
ανεπιθύμητη ενέργεια απευθείας στον ΕΟΦ,
σύμφωνα με το εθνικό σύστημα αναφοράς
ανεπιθύμητων ενεργειών.



Omalin

IRON PROTEIN ACETYL ASPARTYLATE
+ CALCIUM FOLINATE

plus

Η αποτελεσματικότητα του **Omalin**
σε συνδυασμό με **φυλλινικό οξύ...**



Για μια ομαλή
εγκυμοσύνη



Pharmaceutical Laboratories S.A.

www.uni-pharma.gr

ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ (Σ.Π.Χ.)

1. ΟΝΟΜΑΣΙΑ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: OMALIN PLUS® 800 (40 Fe⁺⁺⁺) mg + 0,200 (0,185) mg/15 ml vial πόσιμο διάλυμα σε περιέκτη μιας δόσης. **2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Πόσιμο διάλυμα (φιαλίδιο): Κάθε φιαλίδιο των 15 ml περιέχει 800 mg iron protein acetyl aspartylate, το οποίο αντιστοιχεί σε 40 mg τριθενή σιδήρου. Κόνις (αποθηκευτικό πώμα): Κάθε πώμα περιέχει 0,200 mg calcium folinate, το οποίο αντιστοιχεί σε 0,185 mg φυλλινικού οξέος. **3. ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ:** Πόσιμο διάλυμα σε περιέκτη μιας δόσης. **4. ΚΛΙΝΙΚΑ ΣΤΟΙΧΕΙΑ: Θεραπευτικές ενδείξεις:** Ενδείκνυται σε καταστάσεις ήπιας έλλειψης σιδήρου και για την πρόληψη της αναιμίας κατά την εγκυμοσύνη και το θηλασμό. **Δοσολογία και τρόπος χορήγησης:** 1-2 φιαλίδια την ημέρα (ισοδυναμούν με 40-80 mg τριθενή σιδήρου) διηρημένα σε δύο δόσεις κατά προτίμηση πριν από τα γεύματα. **Αντενδείξεις:** Αιμοσίδρωση. Επικίνδυνος ή κληρονομική αιμοχρωμάτωση. Απλαστική, αιμολυτική και αναιμία χρόνιας νόσου. Χρόνια παγκρεατίτιδα. Κίρρωση. Πρωτοπαθή μεγαλοβλαστική αναιμία από έλλειψη βιταμίνης B12 ή μεγαλοβλαστική αναιμία αδιευκρίνιστης αιτιολογίας. **Ειδικές προειδοποιήσεις και προφυλάξεις κατά τη χρήση:** Η χορήγηση σιδήρου από το στόμα μπορεί να επιδεινώσει τη διάρροια σε ασθενείς με φλεγμονώδη νοσήματα του εντέρου (ελκώδης κολίτιδα, νόσος του Crohn), σύνδρομο δυσαπορρόφησης. Η θεραπεία με σιδηρούχα σκευάσματα μπορεί να έχει ως αποτέλεσμα την εμφάνιση σκούρων-μαύρων κοπράνων. **Ανεπιθύμητες ενέργειες:** Ενδέχεται όμως, ιδιαίτερα σε πολύ υψηλές δόσεις, να εμφανιστούν διαταραχές του γαστρεντερικού συστήματος (διάρροια, ναυτία, δυσκοιλιότητα, επιγαστρικό άλγος), οι οποίες υποχωρούν με την ελάττωση της δόσης ή με τη διακοπή της θεραπείας. (Λ.Τ. 12.86 €).

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα.
Συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ".

INDEX / INVITED FACULTY

A

Despoina Adamidou

Hematologist, Curator of ASY, Thessaloniki General Hospital "Hippocratio", Greece

Dimitrios Agapakis

Director of Department of Internal Medicine, General Hospital Agios Pavlos, Thessaloniki, Greece

Karolina Akinosoglou

Internist - Infectious Diseases Specialist, Associate Professor, Department of Medicine, University of Patras, Dept of Internal Medicine and Infectious Diseases, University General Hospital of Patras,

Michalis Anthopoulos

Medical oncologist, AHEPA University Hospital, Thessaloniki, Greece

Eleni Arnaoutoglou

Professor of Anesthesiology, Faculty of Medicine, University of Thessaly, Chair of Department of Anesthesiology, Larissa University Hospital, Larissa, Greece

Eleftherios Avramopoulos

Mayor of the Municipality of Meteora

B

Anastasia Banti

Hematologist, Hematology Department, Papageorgiou General Hospital, Thessaloniki, Greece

Mettine Bos

Chair of ETHA, Leiden University Medical Center in The Netherlands

Stavroula Bountola

Consultant Hematologist, 1st Medical Propedeutic Dept of Internal Medicine - Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece

Adamantios Bourdakos

MD PhD Internal medicine - Diabetes Director / Internal Medicine Clinic & Diabetes -Lipids-Obesity external unit Trikala General Hospital, Trikala, Greece

C

Omri Cohen

MD, Senior Hematologist & Thrombosis Specialist, Sheba Medical Center; Lecturer, Faculty of Medicine, Tel Aviv University, Israel

D

Stylianios Daios

MD, MSc, PhD, Cardiologist, First Cardiology Department AHEPA University Hospital, Thessaloniki, Greece

Vasiliki Danilatou

Associate Professor in Hematology, School of Medicine, European University Cyprus, Senior Project Manager, Eunomia Limited

Matthaios Didagelos

Interventional Cardiologist, 1st Cardiology Department AUTH, AHEPA University Hospital, Thessaloniki, Greece

Triantafyllos Didangelos

MD, PhD, Professor in Internal Medicine-Diabetology Director of the Diabetes Center, 1st Propedeutic Department of Internal Medicine, Medical School, "AHEPA" Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, President of the Diabetic Neuropathy Study Group (NEURODIAB)

Charikleia Dimitroula

Internist, PhD, Research associate, 1st propedeutic department of Internal medicine, obesity and metabolism outpatient clinic, AHEPA University Hospital, Thessaloniki, Greece

James Douketis

MD, Professor and David Braley-Nancy Gordon Chair in Thromboembolic Disease, McMaster University, Hamilton, Canada

F

Dorothee Faille

PharmD, PhD, Associate Professor in Hematology, Laboratory of Hematology, Bichat Hospital, Paris, France, Paris Cité University, Paris, France

Matilda Florentin

Assistant Professor of Internal Medicine Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

Nikolaos Fragakis

Professor of Cardiology, Director of 2nd Department of Cardiology, Hippokrateion General Hospital, Thessaloniki Aristotle University Medical School, Thessaloniki, Greece

G

Eleni Gavriilaki

Assistant Professor of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece

Argyrios Giannopoulos

Assistant Professor of Vascular Surgery, Aristotle University of Thessaloniki, Thessaloniki, Greece

Fotios Girtovitis

MD, PhD, Hematologist, Curator of Hematology, Blood Center - AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece

Vasiliki Gkalea

Hematologist, Hematology Department Alexandra General Hospital, Athens, Greece

Vasiliki Gougoula

Hematology Resident, 1st Propaedeutic Department of Internal Medicine, AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece

Iason Gravanis-Apostolopoulos

MD, Internal medicine resident, First Propaedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece

Elisavet Grouzi

MD, PhD, Consultant of Haematology, Head of Transfusion Service and Clinical Haemostasis, "St Savvas" Oncology Hospital, Athens, Greece

H

Evdoxia Hatjiharissi

Associate Professor of Hematology, Division of Hematology, 1st Dept. of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece

Emmanouel Hatzipantelis

Professor in Pediatrics-Pediatric Hematology & Oncology, Head, Children's & Adolescent's Hematology-Oncology Unit of 2nd Pediatric Department, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

I

Ignatios Ikonomidis

MD, PhD, FESC, Professor of Cardiology, Member of EACVI, ex.Nucleus member of ESC WG on Aorta & Peripheral Vascular Diseases, Director of Echocardiography and the Laboratory of Preventive Cardiology, 2nd Cardiology Department, National and Kapodistrian University of Athens, Attikon Hospital, Athens, Greece

K

Korina Kaffe

Neurology Resident, 1st department of Neurology, AHEPA University Hospital, Thessaloniki, Greece

Georgia Kaiafa

Associate Professor of Haematology and thromboembolic diseases 1st Propedeutic Clinic of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Greece

Nikolaos Kakaletsis

MD, MSc (Stroke Medicine), PhD, Internal Medicine Physician, Ippokratio General Hospital of Thessaloniki, Postdoctoral Researcher, Medical School, Aristotle University of Thessaloniki, Greece

Charalampos Kakderis

1st Cardiology Department, AHEPA University Hospital, Thessaloniki, Greece

Kallirroï Kalantzi

Associate Professor of Cardiology, University of Ioannina, Ioannina, Greece

Eleni Karlafti

Assistant Professor of Internal Medicine, Aristotle University of Thessaloniki, Greece

Eirini Katodritou

Hematologist, Director, Head of Department of Hematology-Oncology, Theagenion Cancer Hospital, Thessaloniki, Greece

Gili Kenet

Professor of Hematology, Director, National Hemophilia Center, Institute of Thrombosis & Hemostasis, Sheba Medical Center, Head, Amalia Biron Research Institute of Thrombosis

Styliani Kokori

Associate Professor of Hematology, School of Medicine, National & Kapodistrian University of Athens, Athens University General Hospital "ATTIKON", Athens, Greece

Anastasia Kontana

Internist, MD, BSc, cMSc, PhD, A' Propaedeutic Department, AHEPA University Hospital, Thessaloniki, Greece

Zisis Kontoninas

MD, MSc, PhD, Internal Medicine specialist with expertise in Diabetes Medicine, Clinical Reader in Internal Medicine, Aristotle University School of Medicine, 1st Propaedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece

Eleni Korompoki

Assistant Professor of Internal Medicine,
Department of Clinical Therapeutics, National
and Kapodistrian University of Athens, Alexandra
Hospital, Athens, Greece

Maria Kosmidou

Associate Professor of Internal Medicine, AUT,
Papageorgiou General Hospital, Thessaloniki,
Greece

Antonios Kouparanis

Interventional Cardiologist consultant
1st Cardiology DPT Aristotelis University
Thessaloniki AUTH, Thessaloniki, Greece

Ioannis Koutsaliaris

Atherothrombosis Research Centre/Laboratory
of Biochemistry, Department of Chemistry,
University of Ioannina, Ioannina, Greece

Xenofon Krokidis

Director, 2nd Department of Internal Medicine,
General Hospital of Kavala, Kavala, Greece

Elias Kyriakou

MD, PhD, Hematologist, Director, Department
of Laboratory Hematology, Transfusion Medicine
and Hemostasis, Attikon University Hospital,
Athens, Greece

Ioannis Kyriazis

MD, Ph.D, FNSCOPE. Director of Internal Medicine,
Dpt. & Diabetes Outpatient Clinic, KAT General
Hospital, Athens Greece. President of Medical
Society for the Study of Risk Factors for Vascular
Diseases. General Secretary of Hellenic Internal
Medicine Society, General Secretary of Medical
Society for Clinical Applications & Treatment
of Chronic Diseases

Vaia Kyritsi

Gastroenterology resident, MD, MSc, First
Propaedeutic Department of Internal Medicine,
Aristotle University of Thessaloniki, AHEPA
University Hospital, Thessaloniki, Greece

L

Christos Lafaras

MD, PhD, FESC, FHFA, Cardiologist, Director
of Cardio-Oncology Unit, Theagenion Cancer
Hospital, Thessaloniki, Greece

Vaia Lambadiari

Professor of Pathology-Endocrinology,
2nd Pre-Educational Pathology University
Department "ATTIKON" Hospital, Athens, Greece

Eleftheria Lefkou

Haematologist, MD, MPA, PhD, Assistant professor
of Transfusion Medicine, Medical Department,
University of Thessaly, Greece

Sarina Levy-Mendelovich

Senior Pediatric Hematologist, Specialist
in thrombosis and hemostasis, National
Israeli, Hemophilia and Thrombosis Center, Sheba
Medical Center, Israel

Anna-Maria Louka

MD, MSc, PhDc, Astros Health Center, Greece

M

Evangelos-Michail Makris

Hematology Resident 1st Propedeutic Clinic,
hospital, AHEPA University Hospital, Thessaloniki,
Greece

Christof Male

Pediatric Thrombosis & Hemostasis Unit
Department of Pediatrics Medical University
of Vienna

Evdokia Mandala

Professor in Hematology, Head of the Hematology
Department, Forth Department of Medicine,
School of Medicine, Aristotle University of
Thessaloniki, Hippokration Hospital, Thessaloniki,
Greece

Miltiadis Matsagkas

Professor of Vascular Surgery and Chair,
Department of Vascular Surgery, Faculty of
Medicine, University of Thessaly, Greece

Maria Melissopoulou

Cardiologist, 2nd University Clinic of Intensive Care,
"Attikon" University Hospital, Athens, Greece

Lampros Michalis

FRCP, FESC, Professor of Cardiology, Faculty of
Medicine, School of Health Sciences University of
Ioannina, Director, 2nd Department of Cardiology,
University Hospital of Ioannina, Ioannina, Greece

Joao Morais

Cardiologist, Affiliated Professor in Oporto Medical
School. Investigator, Center for Innovative Care and
Health Technology, Leiria, Portugal

Zadalla Mouslech

MD, PhD, Endocrinologist, Lecturer Aristotel
University of Thessaloniki, Director
of the Department of Endocrinology, Diabetes
and Metabolism -Diabetes Center of General
Hospital-Euromedica, Thessaloniki, Greece

Stefanos-Konstantinos Mylonas

Chairman, Department of Internal Medicine
General Hospital of Trikala, Trikala, Greece

N

Dimitrios Nikas

MD, MSc, PhD, FESC, Senior Interventional
Cardiologist, Cardiology Department, Ioannina
University Hospital of Ioannina, Ioannina, Greece

Efrosyni Nomikou

Hematologist, Director, National Health Care
Hematologist, Director, National Health Care System
of Blood Donation, Department of Haemophiliac,
"Hippokration" General Hospital, Athens, Greece

P

Matina Pagoni

Internist, Director and Head, 3rd Department
of Internal Medicine, General Hospital
"G. Gennimatas", Athens, Greece, President
of the Internal Medicine Society of Greece

Emmanouil Papadakis

Hematologist, Co-Editor in Chief Thrombosis
Update, Thrombosis & Hemostasis clinic Ob/Gyn
Hematology Genesis Hospital, Thessaloniki, Greece

Dimitra Papadimitriou

Resident of Internal Medicine, First Propedeutic
Department of Internal Medicine AHEPA University
Hospital, Thessaloniki, Greece

Spyridon-Filippos Papadopoulos

Cardiologist. M.D., AHEPA University Hospital,
Thessaloniki, Greece

Dimitrios Papazoglou

Professor of Internal Medicine, Medical School
of Democritus University of Thrace, Second
University Department of Internal Medicine,
University General Hospital of Alexandroupolis,
Alexandroupoli, Greece

Konstantinos Pappas

Consultant Cardiologist, University Hospital
of Ioannina, Ioannina, Greece

Vasileios Patriarcheas

Internal Medicine Resident, First Propedeutic
Department of Internal Medicine AHEPA University
Hospital, Thessaloniki, Greece

Vasileios Perifanis

Associate Professor in Hematology, Aristotle
University of Thessaloniki, 1st Propedeutic
Department of Internal Medicine, AHEPA University
Hospital, Thessaloniki, Greece

Dimitrios Pilalas

Assistant Professor of Internal Medicine, School
of Medicine, Aristotle University of Thessaloniki
Third Department of Internal Medicine,
Papageorgiou General Hospital, Thessaloniki,
Greece

Georgios Polychronopoulos

Internal Medicine Resident, First Propedeutic
Department of Internal Medicine AHEPA University
Hospital, Thessaloniki, Greece

Charalampos Pontikoglou

Associate Professor of Hematology, University
of Crete School of Medicine, University Hospital
of Heraklion, Heraklion, Crete, Greece

Adonis Protopoulos

Gastroenterologist, 1st Propedeutic Department
of Internal Medicine, Aristotle University of
Thessaloniki, AHEPA University Hospital,
Thessaloniki, Greece

S

Dimitrios Sagris

Consultant in Internal Medicine, Department
of Medicine and Research Laboratory of Internal
Medicine, General University Hospital of Larissa,
Larissa, Greece

Christos Savopoulos

Professor of Internal Medicine, Director
of 1st Medical Propedeutic Dept of Internal
Medicine & Stroke Unit, Aristotle University
of Thessaloniki, AHEPA University Hospital,
Thessaloniki, Greece

Dimitrios Skoutas

MD, PhD Internal Medicine Physician -Specialist
in Diabetes Mellitus, Head of Pathological Sector
of Rehabilitation Center «Anagennisi», Thessaloniki,
Greece. President of Hellenic Association
for the study and education of Diabetes Mellitus

Nikolaos Sousos

Assistant Professor of Haematology - Clinical
Haematology, School of Medicine, University
of Crete, Greece

Alex Spyropoulos

Professor of Medicine, The Donald and Barbara
Zucker School of Medicine at Hofstra/Northwell,
Professor - The Institute for Health Innovations
and Outcomes Research - The Feinstein Institu-tes
for Medical Research; System Director – Anticoa-
gulation and Clinical Thrombosis Services, North-
well Health at Lenox Hill Hospital, New York, USA

INDEX / INVITED FACULTY

Ioannis Styliadis

Consultant Cardiologist, Head of Cardiology Dept. General Hospital "Papageorgiou", Thessaloniki, Greece

T

Thomas J. Tegos

MD, MSc, PhD, Associate Professor of Neurology, A Neurology Department, Aristotelion University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece

Maria Topalidou

Hematologist, consultant in chief of the Hematology department, Papageorgiou Hospital, Thessaloniki, Greece

Konstantinos Toutouzas

Professor of Cardiology, School of Medicine, National & Kapodistrian University of Athens, 1st University Cardiology Clinic General Hospital of Athens "Hippocratio", Athens, Greece

Aikaterini Triantafyllou

Internist and Scientific Collaborator at 1st Propaedeutic Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece

Areti Triantafyllou

Associate Professor of Internal Medicine, Aristotle University of Thessaloniki First Propedeutic Department of Internal Medicine, AHEPA University Hospital Hypertension Outpatient Clinic, Excellent ESH Center of the 1st Propedeutic Dept. of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece

Dimitrios Tsakiris

Visiting Professor of Hematology, Medical School, Aristotle University of Thessaloniki Professor emeritus of Hematology, Medical School, University of Basel, Switzerland

Alexandra Tsankof

First Propedeutic Internal Medicine Clinic University, Intensive Care Unit University, AHEPA University Hospital, Thessaloniki, Greece

Alexandros Tselepis

Emeritus Professor of Clinical Biochemistry, Director of the Atherothrombosis Research Center of the University of Ioannina, Ioannina, Greece

Stavroula Tsiara

MD, PhD, FRCP, Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

V

Sofia Vakalopoulou

Professor of Hematology, Aristotle University School of Medicine, 2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Thessaloniki, Greece

George Vassilopoulos

MD, PhD, Professor, Hematology, University of Thessaly, Head, Department of Hematology, Larisa University Hospital Group Leader, Cell and Gene Therapy Lab, IIBEA, Athens, Greece

Efthymia Vlachaki

Professor in Hematology- Hemoglobinopathies, Aristotle University of Thessaloniki, Thessaloniki, Greece

Z

Dimitrios Zafeiriou

MD, PhD Professor in Child Neurology and Developmental Paediatrics Chair, 1st Department of Pediatrics "Hippokratio" General Hospital Aristotle University, Thessaloniki, Greece

Ioannis Zarifis

MD, PhD, Cardiologist, Head of Cardiology Department, Hospital "G. Papanikolaou", Thessaloniki, Greece

Thomas Zegkos

MD, MSc, PhD, Cardiologist, 1st Cardiology Department, AHEPA University Hospital, Thessaloniki, Greece

Antonios Ziakas

Professor, 1st Department of Cardiology, Aristotle University of Thessaloniki, Thessaloniki, Greece

Eleftheria Ztriva

Internist at First Propedeutic Department of Internal Medicine, AHEPA University Hospital of Thessaloniki PhD Candidate, Aristotle University of Thessaloniki, Greece

REMISSION

POWERED BY **V**

Αύξηση του ποσοστού ύφεσης έναντι της μονοθεραπείας με αζακιτιδίνη στην ΟΜΛ*
Βαθιές ανταποκρίσεις† με σταθερό διάστημα χορήγησης στη ΧΛΛ‡

ΟΜΛ

1L

+ HMA

Θεραπεία για ασθενείς
με νεοδιαγνωσθείσα
ΟΜΛ μη κατάλληλους για
εντατική χημειοθεραπεία¹

ΧΛΛ

1L

+ OBINUTUZUMAB

Σταθερή Διάρκεια
Θεραπείας
1 Έτος¹

2L+

+ RITUXIMAB

Σταθερή Διάρκεια
Θεραπείας
2 Έτη¹

3L+

Μονοθεραπεία

Θεραπεία μέχρι
εξέλιξης της νόσου
ή μη αποδεκτής
τοξικότητας¹

*66% CR+CRi έναντι 28%, P<0,001. †Βαθιές ανταποκρίσεις όπως ορίζονται από την επίτευξη πλήρους ανταπόκρισης (CR) & μη ανιχνεύσιμης ελάχιστης υπολειμματικής νόσου (uMRD), σύμφωνα με τα κριτήρια IWCLL. ‡CR/CRi (INV): 50% (VEN+O) έναντι 23% (O+Clb) (P=0,0001). Αρνητικοποίηση MRD (PB): 76% με VEN+O (95% CI: 69,2-81,1) έναντι 35% με O+Clb (95% CI: 28,8-42,0 p<0,0001) (Πληθυσμός ITT). CR/CRi (INV): 27% (VEN+R) έναντι 8% (BR). Αρνητικοποίηση MRD (PB): 62% με τον συνδυασμό VEN+R (95% CI: 55,2-69,2) έναντι 13% με BR (95% CI: 8,9-18,9) (χωρίς έλεγχο για στατιστική σημαντικότητα).¹

ΟΜΛ=οξεία μυελογενής λευχαιμία, ΧΛΛ=χρόνια λεμφοκυτταρική λευχαιμία, HMA=υπομεθιλωτικός παράγοντας.

Βιβλιογραφία: 1. VENCLYXTO® Περίληψη Χαρακτηριστικών Προϊόντος (ΠΧΠ), Σεπτέμβριος 2024.

Τρόπος Διάθεσης: Περιορισμένη ιατρική συνταγή. Η έναρξη της θεραπείας γίνεται σε νοσοκομείο και μπορεί να συνεχίζεται εκτός νοσοκομείου υπό την παρακολούθηση ειδικού ιατρού.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

ΟΝΟΜΑΣΙΑ-ΜΟΡΦΗ-ΠΕΡΙΕΚΤΙΚΟΤΗΤΑ

ΟΝΟΜΑΣΙΑ-ΜΟΡΦΗ-ΠΕΡΙΕΚΤΙΚΟΤΗΤΑ	ΛΙΑΝΙΚΗ ΤΙΜΗ (€)
VENCLYXTO F.C.TAB 100MG/TAB BTx112 (BLIST 4x28)	4861,73
VENCLYXTO F.C.TAB 100MG/TAB BTx14 (BLIST 7x2)	666,37
VENCLYXTO F.C.TAB 100MG/TAB BTx7 (BLIST 7x1)	342,61
VENCLYXTO F.C.TAB 10MG/TAB BTx14 (BLIST 7x2)	74,37
VENCLYXTO F.C.TAB 50MG/TAB BTx7 (BLIST 7x1)	180,17



Βρείτε την Περίληψη Χαρακτηριστικών του Προϊόντος στις σελίδες που ακολουθούν, ή σκανάρετε το QR code.

Για περισσότερες πληροφορίες απευθυνθείτε στην εταιρεία:

AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.

Μαρίνου Αντύπα 41-45, Νέο Ηράκλειο, 14121, Τηλ.: 214 4165555

abbvie

ZAVICEFTA[®]

ceftazidime and avibactam



Πριν τη συνταγογράφηση συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος που διατίθεται από την εταιρεία.



Pfizer Ελλάς Α.Ε.,
Λ. Μεσογείων 243, Ν. Ψυχικό 15451, Αθήνα, Ελλάδα,
Τηλ. Επικοινωνίας 210-6785800,
Αριθ. Γ.Ε.ΜΗ. 000242901000
Pfizer Ελλάς Α.Ε. (Cyprus Branch)
Λεωφόρος Αθαλάσσας 26, 2018 Λευκωσία, Κύπρος,
Τηλ.: 22817690

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

ΑΥΞΗΣΤΕ ΤΑ ΑΙΜΟΠΕΤΑΛΙΑ, ΕΛΑΦΡΥΝΕΤΕ ΤΟ ΒΑΡΟΣ ΤΗΣ ΘΕΡΑΠΕΙΑΣ¹⁻⁷

Το Doptelet® (αβατρομβοπάγη) είναι ο TPO-RA ο οποίος αυξάνει ταχέως και διατηρεί τον αριθμό των αιμοπεταλίων, χορηγείται από του στόματος, χωρίς διατροφικούς περιορισμούς και χωρίς να απαιτείται παρακολούθηση της ηπατικής λειτουργίας.*^{1,8}



Το Doptelet® ενδείκνυται για τη θεραπεία της πρωτοπαθούς χρόνιας άνοσης θρομβοπενίας (ITP) σε ενήλικες ασθενείς οι οποίοι είναι ανθεκτικοί σε άλλες θεραπείες (π.χ. κορτικοστεροειδή, ανοσοσφαιρίνες).⁸

*Το Doptelet® συνιστάται να λαμβάνεται μαζί με τροφή.⁸
TPO-RA=αγωνιστής του υποδοχέα της θρομβοποιητίνης.

Βιβλιογραφία:

1. Juczak W, et al. *Br J Haematol*. 2018;183(3):479–490. 2. Jain S, et al. *Platelets*. 2023;34(1):2195016. 3. McDonald V, et al. *Hematology*. 2021;26(1):799–808. 4. Al-Samkari H and Nagalla S. *Platelets*. 2022;33(2):257–264. 5. Tsykunova G and Ghanima W. *Ther Clin Risk Manag*. 2022;18:273–286. 6. Oladapo A, et al. *Ther Adv Hematol*. 2023;14:1–11. 7. Song A and Al-Samkari H. *Expert Review of Clin Immun*. 2022;18(8):783–791. 8. Doptelet® EMA Summary of Product Characteristics. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/Doptelet>. (Accessed: April 2025).

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ: Με περιορισμένη ιατρική συνταγή από ειδικό ιατρό και παρακολούθηση κατά τη διάρκεια της αγωγής.

DOPTELET F.C.TAB 20MG/TAB BT x 10 δισκία σε blisters (ALU/ALU) Α.Τ. 624,22€

DOPTELET F.C.TAB 20MG/TAB BT x 15 δισκία σε blisters (ALU/ALU) Α.Τ. 923,63€

DOPTELET F.C.TAB 20MG/TAB BT x 30 δισκία σε blisters (ALU/ALU) Α.Τ. 2111,66€

Dopt/04/Oct2025

Κωδικός: PP-30186

Ημερομηνία ανανέωσης: Οκτώβριος 2025

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Τα Sobi και Doptelet® είναι εμπορικά σήματα της Swedish Orphan Biovitrum AB (publ). ©2025 Swedish Orphan Biovitrum AB (publ) - Με την επιφύλαξη παντός δικαιώματος. Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm Sweden www.sobi.com

Ivor[®]
Bemiparin sodium

IvormaX[®]
Bemiparin sodium



ΣΥΝΟΠΤΙΚΗ ΠΕΡΙΓΡΑΦΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Ivor 2.500 IU anti-Xa/0,2 ml ενέσιμο διάλυμα σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 2.500 IU (anti Factor Xa*) ανά 0,2 ml προγεμισμένη σύριγγα (ισοδύναμη με 12.500 IU (anti Factor Xa*) ανά ml ενέσιμου διαλύματος). Η δραστηριότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηριότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1.

ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ: IVOR 2.500 IU anti-Xa/0,2 ml BT x 2 PFSYR Λ.Τ.: 5,83 €

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Ivor 3.500 IU anti-Xa/0,2 ml ενέσιμο διάλυμα σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 3.500 IU (anti Factor Xa*) ανά 0,2 ml προγεμισμένη σύριγγα (ισοδύναμη με 17.500 IU (anti Factor Xa*) ανά ml ενέσιμου διαλύματος). Η δραστηριότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηριότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1.

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: IvormaX 25.000 IU anti-Xa/ml ενέσιμο διάλυμα σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 25.000 IU (anti-Factor Xa*) ανά ml ενέσιμου διαλύματος. Ισοδύναμη με: 5.000 IU (anti-Factor Xa) ανά 0,2 ml προγεμισμένη σύριγγα, 7.500 IU (anti-Factor Xa) ανά 0,3 ml προγεμισμένη σύριγγα, 10.000 IU (anti-Factor Xa) ανά 0,4 ml προγεμισμένη σύριγγα. * Η δραστηριότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηριότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1. **ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ:** IVORMAX 25.000 IU anti-Xa/ml, BTx2PF. SYRx0,2ML Λ.Τ.: 23,40€, IVORMAX 25.000 IU anti-Xa/ml, BTx2PFSYRx0,3ML Λ.Τ.: 26,43€, IVORMAX 25.000 IU anti-Xa/ml BTx2PFSYRx0,4ML Λ.Τ.: 23,33€

ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ: Ενέσιμο διάλυμα σε προγεμισμένες σύριγγες. (Χρωστικό ή ελαφρώς κίτρινο, διαυγές διάλυμα, ελεύθερο ορατών σωματιδίων). **ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** Προϊόν της LABORATORIOS FARMACEUTICOS ROVI S.A., ΙΣΠΑΝΙΑ. Κάτοχος αδείας κυκλοφορίας: BIANEE A.E., Οδός Βαρυμπόμπης 8, 14671 N. Ερυθραία, Κηφισιά, Τηλ. 210800911. **ΑΡΙΘΜΟΣ(ΟΙ) ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** 24481/26-02-2020, 24482/26-02-2020, 24483/26-02-2020.

ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ: 06-04-2023 (Ivor), 12-07-2023 (IvormaX)

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ: Φαρμακευτικό προϊόν για το οποίο απαιτείται ιατρική συνταγή

Περαιτέρω πληροφορίες διατίθενται από τον ΚΑΚ κατόπιν αιτήσεως.



BIANEE A.E.
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΕΑΝΝΑΚΟΠΟΥΛΟΥ

BIANEE A.E. - Έδρα : Οδός Βαρυμπόμπης 8, 14671 N. Ερυθραία, Κηφισιά
Ταχ. Θυρίδα 52894, 146 10 N. Ερυθραία • Τηλ. : 210 8009111 • Fax: 210 8071573
E-mail: mailbox@vianex.gr • WEBSITE: www.vianex.gr
ΘΕΣΣΑΛΟΝΙΚΗ: Ακαδημίου 113, 562 24 Εύοσμος Θεσσαλονίκης • Τηλ.: 2310 861683

ΑΡ. Γ.Ε.ΜΗ. 000274201000

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



VE-24236-IVO-9/2024

ΔΕΙΤΕ ΤΑ ΑΠΟΤΕΛΕΣΜΑΤΑ ΤΗΣ ΕΡΕΥΝΑΣ ΜΑΣ



PMI SCIENCE

PHILIP MORRIS INTERNATIONAL

**Δημιουργούμε
ένα μέλλον απαλλαγμένο
από το τσιγάρο**

Αναπτύσσουμε εναλλακτικά προϊόντα
χωρίς καύση και αξιολογούμε τις
επιπτώσεις τους στην ατομική και
τη δημόσια υγεία χρησιμοποιώντας
αυστηρές επιστημονικές μεθόδους

Γνωρίστε το PMI Science
pmiscience.com

PMI Science

@pmiscience



*Το παρόν απευθύνεται μόνο σε επιστήμονες
και επαγγελματίες στον τομέα της υγείας*



PLATOREL®

Ροσουβαστατίνη



ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ
Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής,
Τηλ.: 210 6039326-9, Fax: 210 6039300
www.elpen.gr

ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ
Σεβαστείας 11, 115 28 Αθήνα,
Τηλ.: 210 7488711, Fax: 210 7488731
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη,
Τηλ.: 2310 459920-1, Fax: 2310 459269



Αναφέρετε κάθε σκευάζουσα/μυθολογούμενη
αντεπλήρη ενέργεια απευθείας στον ΕΟΦ,
σύμφωνα με το εθνικό σύστημα αναφοράς
αντεπλήρυντων ενεργειών.

ΠΡΟΪΟΝ	Λ.Τ.
PLATOREL F.C.TAB 5MG/TAB BTx30 tabs	6,14 €
PLATOREL F.C.TAB 10MG/TAB BTx30 tabs	13,31 €
PLATOREL F.C.TAB 20MG/TAB BTx30 tabs	18,75 €
PLATOREL F.C.TAB 40MG/TAB BTx30 tabs	23,28 €

Για συνταγογραφικές πληροφορίες συμβουλευτείτε την ΠΧΠ (QR κωδικός) ή απευθυνθείτε στην εταιρεία ELPEN
Φαρμακευτικό προϊόν για το οποίο απαιτείται ιατρική συνταγή.

■ DATE & VENUE

The **Advanced Learning on Platelets and Thrombosis International Course (ALPIC 2025)** will be held from **Friday, November 28th** to Sunday, **November 30th 2025** in **Kalam-paka, Greece**, at **Divani Meteora Hotel**.

The Conference will be only with physical presence of participants.

■ LANGUAGE

The official languages of the Course are **Greek** and **English**. The English language may be used widely especially in the presentations of the speakers to encourage the interaction in all scientific sessions of the English speaking faculty.

■ ABOUT KALAMPAKA

Kalampaka is a town and seat of the municipality of Meteora in the Trikala regional unit, part of Thessaly in Greece. The population was 11,492 at the 2021 census, of which 8,573 in the town proper. The Meteora monasteries are located near the town. Kalam-paka is the northwestern terminal of the old Thessaly Railways, now part of OSE.

The town is situated at the foot of the Meteora massif, a region of sandstone outcrops formed by weathering along criss-cross faults in the foothills of the Chasia Mountains between Thessaly and Macedonia. Evidently an old delta was indurated and raised during orogenesis of the region with a high degree of faulting. Drainage was into the Pineios River Valley.

The entire Meteora massif belongs to one municipal unit, Kalampaka. The city is located at the foot of the massif on the SW side of the massif, which happens to be on the left, or northern, bank of the river, which flows N-S there. The settlements and communities of the municipal unit, named after villages, divide the massif. The other seven municipal units surround Kalampaka, but are not in the massif.

Meteora is a rock formation, hosting one of the most prominent complexes of Eastern Orthodox monasteries, viewed locally as second in importance only to Mount Athos. Twenty-four monasteries were established atop the giant natural pillars and hill-like rounded boulders that dominate the local area, mainly from the second half of the 14th century under the local rule of Simeon Uroš. Six of these are still active and open to visitors: the monasteries of Great Meteoron (est. 1356), Varlaam, Saint Nicholas Anapausas, Rousanou, Holy Trinity, and Saint Stephen. The latter became a community of nuns in 1961, whereas the former five remain managed by monks. Meteora is located in between the town of Kalampaka and the village of Kastraki at the northwestern edge of the Plain of Thessaly near the Pineios river and Pindus Mountains. The Meteora complex was added to the UNESCO World Heritage List in 1988 because of its outstanding architecture and beauty, combined with religious and cultural significance.

GENERAL INFORMATION

■ REGISTRATIONS

Registration Fee: 200.00 euros + 24% VAT

Registration Fee includes:

- Access to Conference & exhibition area
- Conference material (e-program & e-badge)
- e-Certificate of attendance
- Attendance at the organized Coffee breaks during the Scientific Program

■ CERTIFICATE OF ATTENDANCE

19,5 European Continuing Medical Education Credits (ECMECs) will be accredited by the Panhellenic Medical Association (PMA) to medical specialties. The credits will be allocated based on attendance time.

Participants can download their Certificates 2 dates after the end of the Course from the site of Congress World <https://certificates.congressworld.gr/gr/congress>.

■ CONTACT



Congress World

27, Michalakopoulou Ave, 115 28, Athens Greece

Tel: +30 (210) 7210001, 7210052, 7222518, 7210025

E-mail: info@congressworld.gr, www.congressworld.gr

SPONSORS

The Organizers wish to thank the following pharmaceutical companies for their support in the accomplishment of the Course:

abbvie



AstraZeneca

ELPEN



innovis
Future health today



PMI SCIENCE
PHILIP MORRIS INTERNATIONAL



WinMedica

Nilotinib Accord

150 mg

200 mg

ΣΚΛΗΡΑ ΚΑΨΑΚΙΑ



Νοσοκομειακές Τιμές:
 Nilotinib Accord Caps 150mg/CAP BT X 112 (4 X 28 X 1) CAPS
 (ΜΟΝΑΔΑ ΔΟΣΗΣ) (ΠΟΛΛΑΠΛΗ ΣΥΣΚΕΥΑΣΙΑ) ΣΕ BLISTER PVC/PVDC/ALU: 1.115,10 €
 Nilotinib Accord Caps 200mg/CAP BT X 112 (4 X 28 X 1) CAPS
 (ΜΟΝΑΔΑ ΔΟΣΗΣ) (ΠΟΛΛΑΠΛΗ ΣΥΣΚΕΥΑΣΙΑ) ΣΕ BLISTER PVC/PVDC/ALU: 1.486,78 €

Κάτοχος Άδειας
 Κυκλοφορίας:
 Accord Healthcare S.L.U.

accord

Τοπικός Αντιπρόσωπος

WinMedica

Για περισσότερες πληροφορίες:
WIN MEDICA ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.
 Αghαίου 6-8, Μαρούσι 151 23
 Τηλ.: 210 7488821, Fax: 210 7488827
 info@winmedica.gr, www.winmedica.gr

NilotAcc.01/11/2025

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
 Ανορθώστε
 ΟΛΕΣ τις ανεπάρκειες ενόργειας για
 ΟΛΑ τα φάρμακα
 Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ: ΠΕΡΙΟΡΙΣΜΕΝΗ ΙΑΤΡΙΚΗ ΣΥΝΤΑΓΗ. Η ΕΝΑΡΞΗ ΤΗΣ ΘΕΡΑΠΕΙΑΣ
 ΓΙΝΕΤΑΙ ΣΕ ΝΟΣΟΚΟΜΕΙΟ ΚΑΙ ΜΠΟΡΕΙ ΝΑ ΣΥΝΕΧΕΣΤΑΙ ΚΑΙ ΕΚΤΟΣ ΝΟΣΟΚΟΜΕΙΟΥ
 ΥΠΟ ΤΗΝ ΠΑΡΑΚΟΛΟΥΘΗΣΗ ΕΙΔΙΚΟΥ ΙΑΤΡΟΥ

Nilotinib Accord



Πριν την
 συνταγογράφηση
 συμβουλευτείτε
 την Περίληψη
 Χαρακτηριστικών
 Προϊόντος


ALPIC 2025

NOTES

[illegible]

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

Δυο σταγόνες αίμα δεν μοιάζουν ποτέ σαν δυο σταγόνες



Κάθε σταγόνα αίμα είναι διαφορετική. Κάθε ασθενής είναι διαφορετικός.

Για το λόγο αυτό χρειάζεται μια **εξατομικευμένη προσέγγιση**.
Στη **Roche** αναπτύσσουμε **καινοτόμες θεραπευτικές επιλογές** που
προσαρμόζονται στις διαφορετικές ανάγκες των ασθενών κι έχουν
αλλάξει σημαντικά τη θεραπεία των αιματολογικών κακοηθειών.
Για **περισσότερο από 25 χρόνια** επενδύουμε στην έρευνα με
επίκεντρο όχι απλώς τον άνθρωπο, αλλά κάθε άνθρωπο.¹⁻⁵

MabThera® SC
Rituximab Subcutaneous

GAZYVARO®
obinutuzumab

POLIVY®
polatuzumab vedotin

Lunsumio®
mosunetuzumab

COLUMVI®
glofitamab

1. ΠΧΠ προϊόντος MabThera® SC 2. ΠΧΠ προϊόντος Gazyvaro® 3. ΠΧΠ προϊόντος Polivy® 4. ΠΧΠ προϊόντος Lunsumio® 5. ΠΧΠ προϊόντος Columvi®

▼ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Η αναφορά πιθανολογούμενων ανεπιθύμητων ενεργειών μετά από τη χορήγηση άδειας κυκλοφορίας του φαρμακευτικού προϊόντος είναι σημαντική. Επιτρέπει τη συνεχή παρακολούθηση της σχέσης οφέλους - κινδύνου του φαρμακευτικού προϊόντος. Πρέπει να γίνεται αναφορά των ανεπιθύμητων ενεργειών. Οι ανεπιθύμητες ενέργειες θα πρέπει να αναφέρονται ως εξής: Ελλάδα: στη Μονάδα Φαρμακοεπαγρύπνησης της Roche (Hellas) A.E., είτε αποστέλλοντας e-mail (hellas.drugsafety@roche.com), είτε τηλεφωνικώς (+30 210 6166100). Περισσότερες πληροφορίες διατίθενται από τον Κάτοχο άδειας Κυκλοφορίας κατόπιν αίτησης.

Τρόπος διάθεσης: Με περιορισμένη ιατρική συνταγή: Μόνο για νοσοκομειακή χρήση από γιατρό με κατάλληλη ειδικευση και εμπειρία.

POLIVY 140mg/30mg: Κόνις για πυκνό σκεύασμα για παρασκευή διαλύματος προς έγχυση.

140mg: N.T.: 8.243,83 € - Α.Τ.: 9.913,35 €, **30mg:** N.T.: 1.762,45 € - Α.Τ.: 2.145,36 €

Lunsumio 1mg/30mg: Πυκνό διάλυμα για παρασκευή διαλύματος προς έγχυση.

1mg: N.T.: 207,18 € - Α.Τ.: 273,56 €, **30mg:** N.T.: 6.218,38 € - Α.Τ.: 7.477,72 €

COLUMVI 2,5mg/10mg: Πυκνό διάλυμα για παρασκευή διαλύματος προς έγχυση.

2,5mg: N.T.: 751,75 € - Α.Τ.: 939,45 €, **10mg:** N.T.: 3.006,59 € - Α.Τ.: 3.615,47 €

GAZYVARO: Πυκνό διάλυμα για παρασκευή διαλύματος προς έγχυση.

1.000mg: N.T.: 2.221,37 € - Α.Τ.: 2.690,87 €

MabThera SC 1400mg: Διάλυμα για υποδόρια ένεση.

1400mg: N.T.: 1.235,15 € - Α.Τ.: 1.518,05 €

Roche (Hellas) A.E.

Αλαμάνας 4 & Δελφών, 151 25 Μαρούσι, Αττική
τηλ: 210 6166100, email: hellas.medinfo@roche.com
800 111 93 00 Ελλάδα (δωρεάν γραμμή επικοινωνίας)

**Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»**

Xavertia

Ριβαροξαμπάνη



Τρόπος διάθεσης: Με ιατρική συνταγή Λιανική Τιμή Δ.Τ. 09/2025*

XAVERTIA® F.C.TAB 10MG/TAB BT X 30 TABS 46,11€

XAVERTIA® F.C.TAB 15MG/TAB BT X 30 TABS 44,64 €

XAVERTIA® F.C.TAB 20MG/TAB BT X 30 TABS 44,64 €

*Σε περίπτωση έκδοσης νέου δελτίου Τιμών Φαρμάκων ισχύουν οι νεότερες τιμές



Πριν την συνταγογράφηση συμβουλευτείτε την ΠΧΠ του προϊόντος η οποία είναι διαθέσιμη από την εταιρεία εφόσον ζητηθεί ή εναλλακτικά χρησιμοποιώντας το QR-code του υλικού

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε:

ΟΛΕΣ τις ανεπιθύμητες ενέργειες για

ΟΛΑ τα φάρμακα

Συμπληρώνοντας την «**ΚΙΤΡΙΝΗ ΚΑΡΤΑ**»

innovis
Future health today

Innovis Pharma A.E.B.E.

Λεωφ. Κηφισίας 44, Μαρούσι 151 25

T: +30 216 20 05 600, F: +30 210 66 64 804

www.innovispharma.gr

Xv-Adv01-0425